More Neuroscientific Biopharmaceuticals Ltd. news
Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

NSB files new patent

Dec 4, 2022 at 9:45 PM EST · Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · Dec 4, 2022 at 9:45 PM EST

On 6ix: 6ix.com/news/nsb-files-new-patent

Neuroscientific Biopharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Story so far

  • Ethics Approval Granted for Early-Phase Clinical TrialJun 7, 2022
  • Additional US Patent grantedJan 22, 2020

Earlier from Neuroscientific Biopharmaceuticals

  • Appointment of Interim CEONov 22, 2022
  • Investor Update PresentationSep 20, 2022
  • CEO ResignationSep 9, 2022
  • HREC decision to not approve Phase I Clinical TrialSep 6, 2022
  • 2022 Annual Report and Appendix 4EAug 29, 2022

Later from Neuroscientific Biopharmaceuticals

  • R&D Tax Incentive Refund ReceivedFeb 1, 2023
  • Positive treatment effect in MS animal studyMar 14, 2023
  • 2023 Annual Report and Appendix 4EAug 25, 2023
  • Appointment of CEOAug 31, 2023
  • Resignation of CEODec 1, 2023
All Neuroscientific Biopharmaceuticals news releases↗

Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.

Follow Neuroscientific Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer